Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 10 de 10
Filtrer
Plus de filtres










Base de données
Gamme d'année
2.
Clin Exp Dermatol ; 39(4): 443-7, 2014 Jun.
Article de Anglais | MEDLINE | ID: mdl-24825134

RÉSUMÉ

BACKGROUND: Nailfold capillaroscopy is used for the identification of microvascular involvement in many rheumatic and extrarheumatic diseases. AIM: To determine the nailfold capillary changes in patients with Behçet disease (BD) by videodermoscopy, i.e. nailfold videocapillaroscopy (NVC). METHODS: We used a videodermatoscope (Molemax II, × 30 magnification) to perform nailfold capillaroscopy on 40 patients with BD and 40 healthy controls (HC). All nailfold images were evaluated for capillary density, distribution and morphology, assessing features such as enlargement or tortuosity of the capillaries, microhaemorrhages and avascular areas. RESULTS: Enlarged capillaries were detected in 14 patients, microhaemorrhages in 6 patients, and avascular area in 3 patients. There was a statistically significant difference between patients with BD and healthy controls for capillary dilatation and microhaemorrhages (P < 0.05). Capillaroscopic changes were not associated with sex or clinical characteristics. CONCLUSIONS: Using NVC, nailfold capillary changes were apparent in patients with BD, but not in HC. NVC could be a useful technique for evaluating microvascular damage in BD.


Sujet(s)
Maladie de Behçet/anatomopathologie , Vaisseaux capillaires/anatomopathologie , Capillaroscopie , Ongles/vascularisation , Adulte , Études cas-témoins , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte
3.
J Eur Acad Dermatol Venereol ; 25(10): 1168-73, 2011 Oct.
Article de Anglais | MEDLINE | ID: mdl-21214630

RÉSUMÉ

BACKGROUND: There is a need for a laboratory marker that correlates with the clinical activity of Behçet's disease (BD). OBJECTIVE: We aimed to investigate whether serum galectin-3 (Gal-3) levels were affected during the course of the disease with regard to disease activity. METHODS: A total of 131 subjects were involved in the study as follows: Group 1: BD active (n = 39); Group 2: BD inactive (n = 31); Group 3: Disease controls with leucocytoclastic vasculitis confirmed with a skin biopsy (n = 22); and Group 4: Healthy control subjects (n = 39). The BD patients were followed regularly and samples were taken in their active and inactive periods of the disease over a 2-year period. RESULTS: Serum Gal-3 levels were significantly higher in active BD patients (mean 2.38) than inactive BD patients (mean 0.63; P < 0.0001) and the healthy control subjects (mean 0.75; P < 0.0001). There was no significant difference between the leucocytoclastic vasculitis and active BD patients (P = 0.093). Serum Gal-3 levels were positively correlated with clinical activity scores of active BD patients (r = 0.66, P < 0.0001). In addition, the Gal-3 levels were significantly higher in the active disease period when compared with the inactive period during the follow-up. There were no significant differences between the two inactive periods of the disease among the same patients. Further analyses revealed that patients with vascular involvement had significantly higher Gal-3 levels than the other active BD patients (mean 7.57; P = 0.007). LIMITATIONS: The limitation of the study is the small number of patients with vascular involvement in the active BD patient group. CONCLUSION: Gal-3 levels are correlated with the activity of Behçet's disease especially with the vascular involvement.


Sujet(s)
Maladie de Behçet/sang , Évolution de la maladie , Galectine -3/sang , Adolescent , Adulte , Marqueurs biologiques/sang , Biopsie , Études cas-témoins , Femelle , Études de suivi , Humains , Études longitudinales , Mâle , Adulte d'âge moyen , Indice de gravité de la maladie , Peau/anatomopathologie , Vascularite leucocytoclasique cutanée/sang , Jeune adulte
5.
Clin Exp Dermatol ; 35(6): 588-92, 2010 Aug.
Article de Anglais | MEDLINE | ID: mdl-19874331

RÉSUMÉ

BACKGROUND: Laser-assisted hair removal has become a popular treatment for eradication of body hair. Many studies have been published concerning the safety and efficacy of several laser systems. Adverse events are hyperpigmentation, hypopigmentation, erythema, oedema, scarring, pain and blistering. Changes in sweating have not previously been reported. AIM: To investigate the effects on axillary sweating of hair removal by a 1064-nm neodymium:yttrium-aluminium-garnet (Nd:YAG) laser. METHODS: The sweating function of both axillae was evaluated objectively by the iodine starch test for planimetry measurement and subjectively using a visual analogue scale (VAS) before the treatment, and 1 month and 1 year after the last session. RESULTS: The difference in hyperhidrotic activity before and after treatment was significant (P < 0.05), and these differences persisted 1 year after the last evaluation. CONCLUSIONS: The results of this study confirm that treatment of axillary hair using the 1064-nm Nd:YAG laser can cause hyperhidrosis, and this effect is not transient. We did not evaluate the eccrine glands histologically, which is a limitation of the study.


Sujet(s)
Épilation/effets indésirables , Hyperhidrose/étiologie , Lasers à solide/effets indésirables , Sudation/physiologie , Adolescent , Adulte , Aisselle , Épilation/méthodes , Humains , Adulte d'âge moyen , Études prospectives , Statistiques comme sujet , Enquêtes et questionnaires , Jeune adulte
8.
Clin Exp Dermatol ; 31(4): 520-4, 2006 Jul.
Article de Anglais | MEDLINE | ID: mdl-16716153

RÉSUMÉ

BACKGROUND: Psoriasis is a chronic skin disease that often requires long-term therapy to control the symptoms. Combination therapies for severe psoriasis have advantages for disease control and are thought to reduce long-term side-effects. OBJECTIVE: To assess the efficacy and side-effects of methotrexate plus ciclosporin used in combination for the treatment of severe psoriasis. METHODS: In this prospective study, 20 patients were treated with the combination of methotrexate and ciclosporin. Methotrexate was given intramuscularly as a single weekly dose of 10 mg and ciclosporin at a dose of 3.5 mg/kg/day in two equally divided doses. Clinical response was assessed according to clinical outcome and the Psoriasis Area and Severity Index which were evaluated at the beginning of therapy (PASI1), after cessation of one agent (PASI2), and at the end of therapy (PASI3). RESULTS: All the patients had previously received one or more systemic treatment. There were 10 women and 10 men (mean age 44 years). The median (minimum to maximum) duration of methotrexate and ciclosporin treatments were 12.5 (4-55) and 14.0 (4-80) weeks, respectively. Median duration of combination therapy was 9.5 weeks (range 4-50). The median of previously used and end-of-study cumulative doses of methotrexate were 181.8 mg (range 0-785) and 330.8 mg (range 50-845), respectively. The median PASI scores were decreased by 77.4% (range 51.2-90.2) and 75.9% (range 10.1-100) at PASI2 and PASI3, respectively. CONCLUSION: Patients with severe psoriasis had clinically significant improvement after the initiation of combination therapy. Healing rate was decreased upon cessation of one of the medications. Short-term side-effects were minor, transient and manageable. Long-term follow-up of patients treated with this combination is needed.


Sujet(s)
Ciclosporine/usage thérapeutique , Produits dermatologiques/usage thérapeutique , Méthotrexate/usage thérapeutique , Psoriasis/traitement médicamenteux , Adulte , Sujet âgé , Ciclosporine/effets indésirables , Produits dermatologiques/effets indésirables , Association de médicaments , Femelle , Humains , Mâle , Méthotrexate/effets indésirables , Adulte d'âge moyen , Études prospectives , Résultat thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...